A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
Kamel Chettab(Université Claude Bernard Lyon 1), Charles Dumontet(Centre de Recherche en Cancérologie de Lyon)
Cited by 13
Related Papers
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity
|Breast Cancer Research|2015|104
<i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
|Cancer Immunology Research|2022|31